Part, Chapter, Paragraph
1 I, 2. 10. 2| biomarker discovery, and uses in oncology and cardiovascular medicine.
2 II, 5. 3.Acr| European Society for Medical Oncology~EUROCHIP~European Cancer
3 II, 5. 3.Acr| Expectancy~MOSES~Medical Oncology Status in Europe Survey~
4 II, 5. 3. 2| European Society for Medical Oncology (ESMO) addresses global
5 II, 5. 3. 2| performed the ‘MOSES’ (Medical Oncology Status in Europe Survey)
6 II, 5. 3. 2| about the status of medical oncology in Europe through questionnaires.
7 II, 5. 3. 7| differences in the teaching of oncology (particularly, medical oncology)
8 II, 5. 3. 7| oncology (particularly, medical oncology) and the current situation
9 II, 5. 3. 7| organization of medical oncology in the different countries
10 II, 5. 3. 7| to specialists in medical oncology.~· The role of the medical
11 II, 5. 3. 7| into the larger medical oncology community.~ ~The report
12 II, 5. 3. 9| EUROCARE-4 study. Lancet Oncology 8 (9):773-783.~ ~Boyle P,
13 II, 5. 3. 9| ESMO (2006): Medical Oncology Status in Europe Survey (
14 II, 5. 3. 9| EUROCARE-4 data. Lancet Oncology 8 (9): 784-796.~ ~WCRF (
15 II, 9. 3. 1| EUROCARE-4 data." The Lancet Oncology 8(9): 784-796.~ ~Verlato
16 III, 10. 2. 1| version (2003). Annals of Oncology; 14: 973–1005. Available
17 IV, 11. 1. 5| For instance, the surgical oncology and general surgery intensive-care
18 IV, 11. 6. 5| clinical practice guidelines in oncology using the Appraisal of Guidelines
19 IV, 13. 7. 3| the fields of genomics, oncology, cardiovascular medicine,
